Phone
ClinicalTrials.gov URL
NCT Name
NCT04329728
Acknowledgement
48 hours
AVM Biotechnology LLC
EA Therapies for Single Patient
AVM0703 Injection is a novel and proprietary formulation of high concentration (24 mg/mL) of dexamethasone.
It is the subject of two clinical investigations:
• Leukemia and Lymphoma (ClinicalTrials.gov Identifier: NCT04329728)
• ARDS (Acute Respiratory Distress Syndrome) mediated by COVD-19 or Influenza (A or B) (ClinicalTrials.gov Identifier: NCT04366115)
EA Policies for Single Patient
The purpose of our compassionate use program is to make AVM0703 available to those patients who have exhausted other treatment options and who do not meet the criteria to enroll in a clinical trial. It is intended to improve access to AVM0703 for patients with serious or immediately life-threatening diseases or conditions who lack other therapeutic options and may benefit from it.
EA Policies for Disease / Category